Molecular diagnostics company Qiagen has partnered with Element Biosciences to provide complete next-generation sequencing (NGS) workflows for Element’s AVITI System.

The AVITI System is an advanced benchtop sequencing platform that offers a combination of performance, cost, and flexibility for a wide range of NGS applications.

Under the partnership, Qiagen will provide customers using the AVITI System with Sample-to-Insight NGS workflows with its validated QIAseq panels and integrated bioinformatics solutions.

The bioinformatics solutions include CLC LightSpeed and QCI Interpret software.

Qiagen senior vice president, life sciences business area head Nitin Sood said: “Researchers are increasingly searching for complete solutions and workflows from sample to insight, and we are committed to advancing the field together by providing innovative technology and applications that help researchers accelerate discovery.”

Qiagen digital insights senior vice president Jonathan Sheldon said: “There is a huge potential for NGS to deliver on the vision of precision medicine. One of the greatest barriers to ubiquitous adoption and use is the efficient downstream analysis and interpretation of processed samples.

“We are pleased to partner with Element Biosciences to deliver joint solutions that enable customers to rapidly adopt, automate, and scale their NGS needs with higher cost efficiencies and faster turnaround times.”

Qiagen’s QIAseq panels are designed to facilitate accurate NGS library preparation.

Its QIAseq miRNA Library Kit, the QIAseq xHYB Actionable Exome Panel, and the QIAseq Targeted DNA Pro Panel have been validated on the AVITI sequencer.

They showed superior performance, high specificity, and coverage uniformity, along with consistent variant detection.

LightSpeed is a new module for QIAGEN CLC Genomics Workbench Premium, which enables AVITI System users to perform cost-effective whole genome sequencing secondary analysis.

QCI Interpret is a fully customisable software solution that enables NGS variant interpretation and reporting for oncology and hereditary applications.

Element Biosciences corporate and business development senior vice president Yaron Hakak said: “Element and Qiagen share the goals of offering flexible, cost-effective, and high-performance solutions to our customers.

“Jointly promoting the combined workflow will help us serve an expanded customer base with the backing of a global genomic powerhouse like Qiagen.”